医学
溶栓
经皮
导管
外科
肢体缺血
血管内治疗
随机对照试验
下肢
临床试验
梅德林
重症监护医学
缺血
血管疾病
质量管理
血管成形术
作者
Stefan Acosta,Vincent Jongkind,Konstantinos Stavroulakis,Caitlin W. Hicks,Cristina Rocchi,Merli Koitmäe,Jos C. van den Berg
标识
DOI:10.1016/j.ejvs.2025.10.060
摘要
OBJECTIVE: To perform a systematic review and meta-analysis of randomised trials and observational studies assessing outcomes of different endovascular management approaches for the treatment of acute lower limb ischaemia (ALI) when adjusted for Rutherford classification. DATA SOURCES: PubMed, Embase, Cochrane Library, and Web of Science. REVIEW METHODS: A literature search was performed in PubMed, Embase, Cochrane Library, and Web of Science on 30 January 2025. Studies recruiting patients after the year 2000, assessing at least 10 adult patients with ALI, reporting Rutherford classification, and comparing different endovascular management approaches were included. The main outcomes of interest were 30 day death, 30 day major amputation, major bleeding, distal embolisation, acute kidney injury, and fasciotomy. Comparative studies reporting patients undergoing a combination of therapies without a clear order were excluded. If at least three studies reported unadjusted effect sizes, providing Rutherford classification for the groups under comparison, a multiple meta-regression random effects model was used to adjust for disease severity. Evidence certainty was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: = 0%), and Rutherford classification IIb was not statistically significant (p = .58) in the meta-regression model. The level of certainty for the summarised evidence was very low. CONCLUSION: The putative benefit of percutaneous endovascular thrombectomy over continuous catheter directed thrombolysis was not proven. The quality of summarised evidence was very low. Adequately powered high quality randomised trials are needed to assess the comparative efficacy of endovascular therapies in ALI.
科研通智能强力驱动
Strongly Powered by AbleSci AI